This site uses cookies to improve user experience by collecting data. By continuing to use this website, you agree to the use of cookies and similar technologies as described in our Privacy Policy.
CONFIRM
MENU
CLOSE
ACEPODIA IS COMMITTED TO DEVELOPING SAFE, EFFECTIVE AND AFFORDABLE CANCER CURES.

We expand today’s cell therapy landscape and transform cancer treatment to the next generation.

FIND US
Acepodia USA Headquarters
1825 S. Grant Street, Suite 900,
San Mateo, CA 94402,
USA
Acepodia Taiwan Subsidiary
Rm. 7, 17F., No.99, Sec. 1, Sintai 5th Rd.,
Sijhih Dist., New Taipei City 22175,
Taiwan (R.O.C.)
CONTACT US
Tel: +1 (415) 366 7822 Email: info@acepodiabio.com
FOLLOW US
Copyright © 2020 Acepodia Inc.
Privacy Policy Terms of use

ACC

Program
Discovery
Preclinical
Phase I
Phase II
ACE1702
HER2 Targeting, ACC-oNK Cell Therapy
DETAILS
Phase I ​
ACE1831
CD20 Targeting, ACC-NKγδT Cell Therapy
DETAILS
Preclinical ​
ACE1708
PD-L1 Targeting, ACC-NKγδT Cell Therapy
DETAILS
Preclinical ​
ACE1975
Target undisclosed, ACC-NKγδT Cell Therapy
DETAILS
Preclinical ​
ACE2023
Target undisclosed, ACC-NKγδT Cell Therapy
DETAILS
Preclinical ​
ACE2107
Target undisclosed
DETAILS
Discovery ​
ACE2146
Target undisclosed
DETAILS
Discovery ​
We have collaborated with biopharmaceutical partners and academic institutes worldwide.
CONTACT US